@KenPaxtonTX The full First Commandment (Exodus):
“…for I, the Lord your God, am a jealous God, punishing the children for the sin of the parents to the third and fourth generation of those who hate me".
Should that be visible for children in classrooms?
@TrumpDailyPosts Is it really impossible to post something without insults—even at Easter? As President, you have a responsibility to set an example. A bit of respect for others wouldn’t hurt, especially on a day that’s supposed to stand for hope and renewal.
@tomdepotter Interesting discussion! I've never thought about that before. We use ~ 0.8 min of fluoro per procedure at 3 fps, resulting in ~20 µGy·m² DAP. Given typical scatter exposure estimates (0.1–1 nSv per µGy·m²), this would correspond to an operator dose of ~2–20 nSv per ablation.
We have reached a major milestone in the PROFID EHRA trial and are proud to announce that the first patient has been enrolled in Bad Segeberg, GER. On behalf of the chief investigator, @GerdHindricks, we would like to thank you all for your contribution!
https://t.co/2yfcPkOO49
We've enrolled our 1st patient for the PROFID EHRA trial today. We are eager to understand the role of prophyl. ICD implantation in pts with LVEF ≤ 35% after MI under modern OMT for the primary prev of SCD
https://t.co/1Z7TpCmB9w
@PROFID_EU @nikdagres @GerdHindricks@Phiso_de
The first study site participating in the PROFID EHRA trial was initiated yesterday at Heart Center Bad Segeberg. Thanks a lot to the PI Dr. Borlich (@MartinBorlich) and his team for the support. And thanks to our CRO, CRI, for the extensive preparation. This was great team work!
Great spirit at the NOAH Investigator Meeting celebrating a successful collaboration and result presentation @ESCCongress. A big thank you to all investigators and partners! #NOAHtrial#anticoagulation#ESC2023#ESCCongress
@sebFeickert An increased bleeding rate with Edoxaban compared to ASA/Placebo was expected from the beginning. What was unexpected was the lack of benefit from Edoxaban or the low stroke rate in patients on ASA/Placebo. A quote from today's inv. meeting: "No pain without gain".